Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Patient centricity is a priority for Merck and its Executive Vice President ... outlines what practical steps the company is taking to improve life for patients and carers. Unfortunately ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Affecting as many as 9 million people across the globe, cancer cachexia is a life-threatening condition ... first approval for the given indication. Merck (MRK) has been one of the stocks most ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

(Reuters) - Merck has stopped two separate late-stage studies of its immunotherapy Keytruda in patients with skin and lung cancers, the company said on Thursday, marking the latest set of trial ...

A Merck & Co. effort to move its PD-1 behemoth ... What’s more, patients’ life expectancy also didn’t favor Keytruda, although the overall survival endpoint was not formally tested because ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...

Blockbuster cancer drug combined with chemotherapy improved survival rates in a Phase 3 trial Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster ...